MedTrace Logo

A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan

NCT00199290 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 267

Last updated 2008-02-05

No results posted yet for this study

Summary

This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis, in order to verify the superiority of Trafermin to placebo, and to determine the recommended therapeutic dose.

Conditions

  • Periodontitis

Interventions

DRUG

Trafermin (genetical recombination)

Sponsors & Collaborators

  • Kaken Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Makoto Tamura, Ph.D · Kaken Pharmaceutical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2007-07-31
Completion
2007-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199290 on ClinicalTrials.gov